photo #1704342

Jeff Rieman on December 15, 2021

7 views

In Album: Jeff Rieman's Timeline Photos

Dimension: 927 x 927

File Size: 99.7 Kb

View More View Less

William Burrell

12-15-21 POSTED: WIMKIN-FACEBOOK-LINKEDIN FOR COVID-19 SAVE YOUR LIFE WITH IVERMECTIN: ... View More12-15-21 POSTED: WIMKIN-FACEBOOK-LINKEDIN FOR COVID-19 SAVE YOUR LIFE WITH IVERMECTIN: Am J Ther. 2021 Jul-Aug; 28(4): e434–e460. Published online 2021 Jun 21. doi: 10.1097/MJT.0000000000001402 PMCID: PMC8248252 PMID: 34145166 Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines Andrew Bryant, MSc,1,* Theresa A. Lawrie, MBBCh, PhD,2 Therese Dowswell, PhD,2 Edmund J. Fordham, PhD,2 Scott Mitchell, MBChB, MRCS,3 Sarah R. Hill, PhD,1 and Tony C. Tham, MD, FRCP4 Author information Copyright and License information Disclaimer COVID-19 STUDIES>>>This article has been cited by other articles in PMC. Go to: Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection. Data sources: We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion. Therapeutic Advances: Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%).

View Less

December 15, 2021